Cluster Headache — Diagnosis, Bridge Treatment, and When to Refer
Cluster headache is not migraine — PA pathway, ICD-10 codes, oxygen as a DME benefit, and acute treatment are entirely different.
PA impact: This card directly affects prior authorization outcomes. Documentation language from this card can be used in PA letters and appeals.
Cluster headache is not migraine and cannot be treated or coded as migraine. The two conditions share severe head pain and nothing else clinically relevant for treatment. Cluster headache attacks are strictly unilateral, last 15 to 180 minutes (not 4–72 hours like migraine), occur with prominent ipsilateral autonomic signs (lacrimation, nasal congestion, conjunctival injection, ptosis, miosis, forehead sweating), and the patient is typically agitated and unable to lie still — the opposite of migraine. Use G44.0xx codes for cluster headache. Filing a cluster headache PA under G43.xxx produces an automatic denial because the treatment pathway is different.
Refer to a headache specialist — but don't wait for the appointment to treat. Cluster headache management at its most complex requires specialist expertise, and for a new diagnosis you should refer. But with a specialist wait of six months or more in most of the country, a patient having up to eight severe attacks per day cannot wait. Initiate treatment while the referral is pending. The rest of this card covers what to start.
Acute treatment: oxygen and subcutaneous sumatriptan are both Level A. High-flow oxygen at 12–15 liters per minute via non-rebreather mask for 15–20 minutes aborts attacks in approximately 78% of patients and has no medication overuse risk — prescribe it for every cluster patient. Equipment goes through DME benefit, not pharmacy benefit: HCPCS codes E0439 or E1392 for the concentrator, A4621/A4622 for the mask. This is one of the most common claim failures in cluster headache management — submitting oxygen through pharmacy produces a denial that has nothing to do with medical necessity. Subcutaneous sumatriptan 6mg (not oral) is the other Level A acute treatment — it works faster than oral forms and cluster attacks don't allow time for oral absorption.
Bridge treatment while verapamil titrates: prednisone taper. Verapamil is the first-line preventive for cluster headache and takes 2–4 weeks to reach therapeutic effect. The standard bridge is a prednisone taper — 60–100mg daily for 4 days, then decrease by 10mg every 3–4 days over 2–3 weeks. Document this as bridge treatment to establish the treatment timeline for any subsequent PA.
Starting verapamil in primary care. Begin at 240mg daily and titrate by 120–240mg every 3–7 days as tolerated. Therapeutic cluster doses often reach 480mg or higher — ECG monitoring is required at doses above 480mg to detect heart block. This is manageable in primary care if you are comfortable with ECG interpretation; otherwise, refer cardiology for the monitoring component while continuing to manage the headache condition.
Galcanezumab (Emgality) 300mg is the only FDA-approved CGRP for cluster — episodic only. The dosing is 300mg monthly given as three 100mg injections — different from the 120mg migraine dose; the PA and NDC are different as well. Most payers require documented failure of verapamil and/or lithium before approving galcanezumab for cluster. The Vault's PA search differentiates between migraine and cluster pathways automatically.
What the specialist adds that primary care cannot easily provide. Greater occipital nerve blocks, inpatient DHE protocols, and neuromodulation devices (the Gammacore noninvasive vagus nerve stimulator has FDA clearance for cluster) require procedural training or inpatient access most primary care settings don't have. Chronic cluster headache — defined as cluster periods lasting more than one year without remission or with remission periods shorter than three months — warrants specialist management from diagnosis.
Ready to run a PA?
The PA Engine applies this guidance automatically — paste a clinical note and get a complete, payer-specific PA letter in under a minute. Free, no account required.
Run a PA — free →Citations: AHS Cluster Headache Guidelines — Robbins MS et al., Headache 2016;56(7):1093-1106. doi:10.1111/head.12866 | Cohen AS et al., Neurology 2009;72(4):341-345 (oxygen evidence) | FDA galcanezumab label (episodic cluster indication).